MediQuest receives EU patent for skin lightening technology

This is the first patent awarded to the company for skin lightening technology. The company’s patented technology uses small molecule inhibitors to regulate a key enzyme within skin melanocytes that is responsible for producing melanin, which is the pigment found in the skin, hair, and eyes.

Individuals affected by skin disorders in which too much pigment is present, such as age spots and melasma, could benefit, the company said.

Thomas Dooley, chief scientific officer of MediQuest, said: “This patent provides us with a new platform to develop topical products for dermatological and cosmeceutical purposes. This is another step in the company’s progress and continued efforts in developing topical formulations to treat skin disorders.”